Jing Zhang | Medicinal Chemistry | Best Researcher Award

Published on by Cognitive Scientist Awards

Dr. Jing Zhang | Medicinal Chemistry | Best Researcher Award

School of Life Sciences and Engineering | China

Dr. Jing Zhang, currently a lecturer at the School of Life Sciences and Engineering, Lanzhou University of Technology, is a dedicated scholar with a strong academic foundation built at Wuhan University, where she completed her bachelor’s and master’s studies in pharmaceutical sciences and medicinal chemistry and later earned a doctorate in pharmaceutical sciences. Her professional journey includes valuable research experience as a research intern at the Chinese Academy of Sciences in the Department of Magnetic Resonance Imaging, which enhanced her expertise in imaging technologies and drug delivery systems. Her research interests lie in the fields of nanomedicine, drug delivery, photodynamic and photothermal therapies, fluorine-based magnetic resonance imaging, and cancer therapeutics. She has contributed significantly to these domains through publications in high-impact journals such as Chemistry & Biodiversity, Advanced Healthcare Materials, The Journal of Organic Chemistry, and Chemical Communications, focusing on anticancer agents, traceable biomaterials, and estrogen receptor modulators. Dr. Zhang’s research skills span organic synthesis, polymer chemistry, molecular imaging, and the development of multifunctional nanocarriers for cancer treatment. Her achievements are further supported by prestigious research funding, including national and provincial projects and collaborations with pharmaceutical industries. Recognized for her diligence and truth-seeking approach, she continues to advance biomedical innovation with the potential to impact cancer diagnosis and therapy significantly, making her a promising leader in pharmaceutical sciences.

Profile: ORCID

Featured Publications

Michela Simone | Boron Neutron Capture Therapy | Best Researcher Award

Published on by Cognitive Scientist Awards

Dr. Michela Simone | Boron Neutron Capture Therapy | Best Researcher Award

Commonwealth Scientific and Industrial Research Organisation | Australia

Dr. Michela Simone is a distinguished scientist with expertise spanning green chemistry, renewable energy, carbohydrate chemistry, glycobiology, ionic liquids, spectroscopy, medicinal chemistry, and synthetic developments. With a multicultural background and fluency in multiple languages, she has built a global research profile, contributing significantly to sustainability and pharmaceutical sciences. Currently serving as a Research Scientist at CSIRO in Australia, she leads and supports projects focused on sustainable carbon technologies and carbon capture efficiency. Her earlier career included leadership as a CERC Fellow at CSIRO, lecturer roles at the University of Newcastle and University of Sydney, and postdoctoral research at the University of Oxford and University College London. She has published extensively in high-impact journals, authored book chapters, and holds patents in hydrogen production and drug development. Her academic and industrial collaborations highlight her interdisciplinary approach, bridging fundamental research with applied solutions to address pressing global challenges in energy, health, and sustainability.

Profile

Google scholar

ORCID

Education

Dr. Michela Simone earned her Doctor of Philosophy from the University of Oxford, where she conducted pioneering research on branched sugar lactones under the mentorship of Professor George W. J. Fleet at the Dyson Perrins Laboratory and Chemistry Research Laboratory. Prior to this, she completed her Master of Science with first-class honours at the Victoria University of Manchester, focusing on the synthesis of muscarinic receptor agonists under Professor E. James Thomas. During her studies, she was awarded a European Union Socrates Award for an exchange program at the Georg-August University of Göttingen in Germany, where she worked on chemical and biological syntheses of pyripyropenes under Professor Uwe Beifuss. This international academic training provided her with a strong foundation in synthetic organic chemistry, carbohydrate chemistry, and medicinal chemistry. Her educational journey laid the groundwork for her later achievements in spectroscopy, drug discovery, and renewable energy research, demonstrating her ability to bridge chemistry with interdisciplinary applications.

Experience

Dr. Michela Simone’s professional journey reflects a balance of academic scholarship, research innovation, and industrial collaboration. Currently, she works at CSIRO as a Research Scientist in the Sustainable Carbon Technologies Group, where she applies her mechanistic and spectroscopic expertise to optimize carbon capture processes for industrial applications. Previously, as a CERC Fellow at CSIRO, she led a major project on sustainable hydrogen production, integrating physical chemistry, engineering, and physics, resulting in a patent for water-splitting processes. Her academic career includes tenure as a Lecturer in Medicinal Chemistry and Chemical Biology at the University of Newcastle, where she managed a 40:40:20 workload across research, teaching, and service while supervising her research group in glycobiology and synthetic chemistry. Earlier, she was a Lecturer in Chemistry at the University of Sydney, focusing on medicinal and biological chemistry. Her postdoctoral work at Oxford and University College London contributed to advances in protein interactions and medicinal chemistry.

Awards and Honors

Dr. Michela Simone’s career has been marked by recognition for her contributions to chemistry and interdisciplinary research. She has authored more than sixty-five peer-reviewed publications, invited book chapters, and holds patents in hydrogen production technologies and drug delivery systems, reflecting her innovative impact on both energy and healthcare. Her invited contributions to special issues in journals such as Molecules, Pharmaceuticals, and the European Journal of Medicinal Chemistry highlight her status as a recognized expert in boron chemistry, glycobiology, and green synthetic methods. She has been invited to contribute book chapters with leading publishers including Taylor & Francis, underscoring her international reputation. Her work has been spotlighted in editorial features such as “Women in Bioorganic Chemistry,” reflecting her role as a leader and role model in science. With a growing citation record, high h-index, and strong collaborations across academia and industry, she continues to be acknowledged for her research excellence and scientific leadership.

Research Focus

Dr. Michela Simone’s research focus lies at the intersection of green chemistry, renewable energy, and medicinal chemistry, with an emphasis on practical applications that address urgent global challenges. She has pioneered work in renewable fuels, including hydrogen generation, biomass conversion, carbon capture and storage, and redox flow batteries, aiming to reduce environmental impact while improving energy efficiency. Her work in carbohydrate chemistry and glycobiology has contributed to the development of high and low Fsp3 drug leads, with innovative approaches incorporating organic boron as a novel pharmacophore for medicinal chemistry and cancer therapies. She has also advanced the field of ionic liquids, exploring their potential in sustainable synthesis and material applications. Utilizing spectroscopy and mechanistic insights, she combines fundamental chemical principles with applied solutions, leading to patents and industrial collaborations. Her interdisciplinary approach integrates chemistry, physics, and engineering, establishing her as a global leader in research that bridges sustainability, energy innovation, and health.

 

Publications

 

Title: Endothelial C-type natriuretic peptide maintains vascular homeostasis
Year: 2014
Citation: 187

Title: The expanding utility of continuous flow hydrogenation
Year: 2015
Citation: 144

Title: Synchrotron based NEXAFS study on nitrogen doped hydrothermal carbon: Insights into surface functionalities and formation mechanisms
Year: 2017
Citation: 126

Title: A compendium of sugar amino acids (SAA): scaffolds, peptide-and glyco-mimetics
Year: 2007
Citation: 121

Title: Selective inhibition of the mitochondrial permeability transition pore protects against neurodegeneration in experimental multiple sclerosis
Year: 2016
Citation: 111

Title: A compendium of cyclic sugar amino acids and their carbocyclic and heterocyclic nitrogen analogues
Year: 2013
Citation: 103

Title: Kiliani on ketoses: branched carbohydrate building blocks from D-fructose and L-sorbose
Year: 2004
Citation: 87

Title: Kiliani reactions on ketoses: branched carbohydrate building blocks from D-tagatose and D-psicose
Year: 2005
Citation: 79

Title: o-Vanillin Derived Schiff Bases and Their Organotin(IV) Compounds: Synthesis, Structural Characterisation, In-Silico Studies and Cytotoxicity
Year: 2019
Citation: 52

Conclusion

Dr. Michela Simone is an accomplished scientist whose interdisciplinary expertise in green chemistry, renewable energy, carbohydrate chemistry, and medicinal chemistry has led to impactful research, patents, and collaborations that advance sustainability and healthcare innovation worldwide.

Andreea-Teodora IACOB | Biomedical Applications of polymeric materials | Best Researcher Award

Published on by Cognitive Scientist Awards

Dr. Andreea-Teodora IACOB | Biomedical Applications of polymeric materials | Best Researcher Award

Dr. Andreea-Teodora Iacob is a dedicated Lecturer PhD and Specialist Pharmacist at the Department of Pharmaceutical Chemistry, Faculty of Pharmacy, “Grigore T. Popa” University of Medicine and Pharmacy Iași, Romania. She has established a remarkable profile in the fields of pharmaceutical chemistry, drug design, and advanced polymeric systems for biomedical applications. With an impressive academic and professional trajectory, Dr. Iacob has contributed extensively to multidisciplinary research on heterocyclic compounds, nanostructured drug delivery systems, and wound healing materials. She holds multiple specialist certifications in pharmaceutical laboratory, clinical pharmacy, and the pharmaceutical-cosmetic industry. She has co-authored over 47 ISI-indexed publications, edited scientific volumes, and has been awarded several national and international accolades for her scientific contributions. Passionate about research, teaching, and collaboration, Dr. Iacob actively mentors students and serves as an editor and reviewer for reputed journals, while also engaging in national and international collaborative projects across pharmaceutical sciences.

Profile

🎓 Education

Dr. Iacob’s academic formation is grounded in pharmaceutical sciences, with a progressive specialization in both academic and clinical domains. She completed her Doctorate in Pharmaceutical Chemistry with research focusing on innovative biomaterials for wound management. In 2018, she earned certification as a Specialist Pharmacist in Pharmaceutical Laboratory from “Saint Spiridon” Clinical Hospital, Iași. In 2021, she added a second specialty in Clinical Pharmacy, and in 2025, she will complete her third specialty in Pharmaceutical and Cosmetic Industry. She enriched her academic background with a postdoctoral research fellowship (2019–2021) at the Faculty of Applied Chemistry and Materials Science in Bucharest, developing novel chitosan/PEO-based films for wound healing. Her academic journey is further enhanced by intensive involvement in national doctoral and postdoctoral training projects. Her education is marked by a continuous commitment to learning, research innovation, and application of chemistry and pharmacology for therapeutic benefit, laying the foundation for her dynamic research and teaching career.

🧪 Experience

Dr. Andreea-Teodora Iacob has over a decade of rich academic and clinical experience. Since February 2020, she serves as a Lecturer PhD in Pharmaceutical and Therapeutic Chemistry at UMF Iași, where she contributes to both undergraduate and postgraduate education. She began her clinical specialization as a pharmacist in 2018 and evolved through additional specializations in clinical pharmacy and pharmaceutical industries. From August 2019 to January 2021, she pursued postdoctoral research in chemical engineering, focusing on polymeric wound dressings. Her expertise spans drug synthesis, physicochemical characterization, nanotechnology, and biomedical formulations. Dr. Iacob has also participated in several European-funded training programs aimed at developing applied research and entrepreneurship skills. Her work encompasses laboratory management, student supervision, and interdisciplinary research. Additionally, she contributes to curriculum development and academic publishing, while maintaining active collaborations with national and international institutions. Her balanced experience in teaching, clinical practice, and research distinguishes her as a versatile pharmaceutical professional.

🏅 Awards and Honors

Dr. Iacob has received wide recognition for her innovative research. She won the Bronze and Silver Medals at EuroINVENT 2025 in Iași, acknowledging her contributions to wound healing and pharmaceutical formulations. She was among the five winners of the L’Oréal-UNESCO For Women in Science Young Talents Romania Program 2023, a prestigious award that supports early-career female researchers. Her papers have earned Best Paper Awards at multiple International Scientific Conferences, including “Applications of Chemistry in Nanosciences and Biomaterials Engineering.” With an H-index of 13 (WOS) and 16 (Google Scholar), her work has been cited over 1000 times, highlighting her influence in the scientific community. She also serves as a Guest Editor for Polymers and Pharmaceutics, and as a substitute member of the COST EU Action CA19140, promoting advanced ion technologies. These honors showcase her dedication to impactful research, leadership in academia, and commitment to promoting women in science.

🔬 Research Focus

Dr. Iacob’s research bridges pharmaceutical chemistry, nanotechnology, and regenerative medicine. Her expertise centers on the synthesis of heterocyclic compounds (azetidin-2-ones, thiazolidine-4-ones, azomethines, hydrazones) with therapeutic potential, including antimicrobial, antioxidant, anti-inflammatory, and cytotoxic activities. She is also deeply involved in the design and evaluation of polymeric biomaterials such as hydrogels, sponges, and films, especially chitosan-based systems, for skin and wound therapy. She has pioneered work on electrospun nanofibers and niosomes, exploring their structural, functional, and biological characteristics for use in chronic wound healing. Her work integrates advanced synthesis methods, spectral analysis (IR, NMR, HRMS), and in vitro biological evaluation. She contributes to eight national and two international research projects and collaborates with leading institutions across Europe. Her multidisciplinary research reflects a commitment to translational science, bridging fundamental chemistry with practical medical applications, especially in skin regeneration, controlled drug delivery, and therapeutic polymer design.

✅ Conclusion

Dr. Andreea-Teodora Iacob is an accomplished pharmaceutical chemist and educator whose impactful contributions in heterocyclic drug design, nanostructured wound therapies, and polymeric biomaterials—supported by high-impact publications, patents, national and international projects, and prestigious awards—make her a leading figure in pharmaceutical research and an outstanding nominee for the Best Researcher/Women Research Award.

Publications

Jim Jinn-Chyuan Sheu | Precision medicine | Best Researcher Award

Published on by Cognitive Scientist Awards

Dr. Jim Jinn-Chyuan Sheu | Precision medicine | Best Researcher Award

Dr. Jim Jinn-Chyuan Sheu is a professor at the Institute of Biomedical Sciences, National Sun Yat-sen University, Taiwan, and an adjunct professor in several prestigious institutions. With a PhD in Life Science from National Tsing-Hua University, his academic and industrial experiences span cancer genetics, precision medicine, and biopharmaceuticals. He has held positions at Johns Hopkins Medical Institutions and Development Center for Biotechnology. His research explores molecular mechanisms underlying diseases such as cancer and endometriosis, employing genome-wide technologies to identify biomarkers and drug targets. He actively contributes to biomedical innovation, translational medicine, and mentorship. Dr. Sheu has received numerous national and international awards, including the Wu-Da-You Memorial Award and Sigma Xi membership. He is also an ambassador for the European Association for Cancer Research. As a prolific researcher and reviewer, he plays key roles in research councils and institutional review boards, helping shape scientific policy and translational biomedical advancements in Taiwan and beyond.

Profile

Education 🎓

Dr. Sheu earned his Ph.D. in Life Science from National Tsing-Hua University, Taiwan, in 2002, where he focused on advanced molecular biology, gene expression regulation, and biomedical research. His doctoral training provided a strong foundation in cancer genetics and systems biology. Earlier, he completed his B.S. in Biology (now Life Science) from Fu-Jen University in 1994, building core competencies in biological sciences and cellular mechanisms. These educational milestones equipped him with theoretical knowledge and technical skills in genomics, proteomics, and cellular signaling, which are now reflected in his research on chromatin remodeling, cancer biomarkers, and therapeutic targets. Through rigorous academic mentorship, Dr. Sheu gained early exposure to multidisciplinary research and critical analysis, fostering his interest in precision medicine. His academic background laid the groundwork for his contributions to biomedical research, drug development, and translational science. These formative years in Taiwan’s top universities underpin his long-standing excellence in scientific discovery and innovation.

Experience 👨‍🏫

Dr. Sheu’s professional experience includes faculty roles and research leadership across academia and industry. He has served as a Professor at National Sun Yat-sen University since 2014 and previously held faculty roles at China Medical University. Internationally, he was a Research Fellow at Johns Hopkins Medical Institutions (2004–2006). Between 2003–2004, he worked in various leadership positions at the Development Center for Biotechnology, including Director of Protein Drugs Division and Project Leader. His postdoctoral and early research roles included work with Dr. Tse-Wen Chang and Dr. Carmay Lim at Academia Sinica. His academic leadership includes roles such as Associate VP of R&D, Chair of the Institute of Biomedical Sciences, and Director of Research Resources at NSYSU. He has reviewed research proposals for numerous hospitals and institutions, served on IRBs, and guided government research policy. His diverse experience bridges basic science, translational research, and biomedical entrepreneurship with national and global impact.

Awards & Recognitions 🏅

Dr. Sheu has received over 30 prestigious awards. In 2023 alone, he earned the Tien-Te Lee Award, NSYSU Outstanding Faculty Award, and top honors at the 37th Joint Biomedical Conference. He previously received the Prof. Chii-Ruey Tzeng Award, Sigma Xi membership (2021), and EACR Ambassador role (2020). His innovation was recognized by Future Tech Award and the 2020 Smart Life Innovation Competition. His studies were featured as Taiwan Research Highlights and F1000Prime recommendations. He was the 2014 recipient of the Wu-Da-You Memorial Award and the IBC Outstanding Scientific Achievement Award. He received the Medical Young Investigator Award in 2009 and the Best Basic Science Award at Johns Hopkins in 2005. As a government-financed scholar to the U.S., his academic excellence has been internationally recognized. He consistently ranks among Taiwan’s top biomedical researchers, illustrating his impact through award-winning research in endometriosis, cancer stemness, diagnostics, and therapeutic innovation.

Research Interests 🔬

Dr. Sheu’s research focuses on cancer genetics and genomics, endometriosis, precision medicine, chromatin remodeling, cytoskeletal dynamics, cell adhesion and invasion, and mechanotransduction. His lab investigates how abnormalities in gene expression and chromatin structure drive disease progression, especially in gynecologic cancers and endometriosis. By applying genome-wide analysis and bioinformatics, his team identifies disease-driving genes and develops novel diagnostic tools and therapeutic strategies. A key interest is the tumor microenvironment and how cytoskeletal networks and nuclear architecture influence cancer stemness and metastasis. His group explores traditional Chinese medicine compounds and stem cell therapies, advancing integrative approaches to medicine. Antibody and vaccine engineering are also integral to his translational pipeline. Funded by NSTC Taiwan and other institutions, his projects target non-invasive diagnostics and biomarker-based interventions. His long-term vision involves bridging molecular biology, clinical application, and therapeutic innovation to impact patient care and global health through interdisciplinary and precision-driven biomedical science.

Publications

Guadalupe Gabriel Flores-Rojas | Smart polymers | Best Researcher Award

Published on by Cognitive Scientist Awards

Dr. Guadalupe Gabriel Flores-Rojas | Smart polymers | Best Researcher Award

Guadalupe Gabriel Flores Rojas is a highly accomplished chemical scientist with expertise in synthesizing materials with antimicrobial and photophysical properties. With a PhD in Chemical Sciences from UNAM, his research spans enzyme immobilization, nanomaterials, dendritic polymers, and drug delivery systems. He has contributed significantly to radiation-induced polymerization, organometallic chemistry, and environmental remediation. Dr. Flores Rojas has held postdoctoral fellowships at top Mexican research institutions and currently serves at the University Center for Exact Sciences and Engineering (UDG). His prolific publication record and editorial roles demonstrate his commitment to advancing polymer science, nanotechnology, and bioactive materials.

Profile

Education 🎓

Guadalupe Gabriel Flores Rojas earned a PhD in Chemical Sciences from UNAM’s Institute of Nuclear Sciences (2014–2018), with a thesis on antimicrobial biomaterials for enzyme immobilization. He completed an MSc in Chemistry at UNAM’s Institute of Chemistry (2010–2012), focusing on Pd(II) catalysts for C–C coupling. He holds a bachelor’s in Industrial Chemistry with a macromolecules specialization from UNAM’s Cuautitlán campus (2006–2010), where he synthesized dendrimers for photonic applications. Earlier, he obtained his Chemical Technician diploma and a Microcomputer Operation diploma from CETIS No. 32 (2003–2006), building a strong foundation in analytical techniques and computer literacy for scientific applications.

Experience 👨‍🏫

Dr. Flores Rojas currently holds a postdoctoral fellowship at UDG, focusing on antimicrobial polymeric materials and nanoparticle-loaded systems for wastewater treatment. He previously worked at UNAM’s Materials Research Institute (2018–2020), designing dendritic photophysical compounds, and at the Institute of Nuclear Sciences (2018), synthesizing biopolymeric materials for controlled drug delivery via gamma radiation. His experience includes evaluating polymer mechanics, SEM/AFM imaging, EPR/NMR/MS spectroscopy, and supervising students. Earlier, he taught mathematics at CETIS No. 32 (2008), demonstrating strong analytical instruction skills. Across roles, he contributes as a journal reviewer, guest editor, and mentor while publishing extensively in international journals.

Awards & Recognitions 🏅

Dr. Flores Rojas has received recognition through prestigious postdoctoral fellowships from Mexico’s top institutions including UNAM and UDG. He serves as a guest editor at MDPI’s Polymers journal and actively reviews for international journals, reflecting peer recognition of his expertise. His leadership roles in scientific conferences like POLYMAT 2019 and his involvement in editorial contributions highlight his professional reputation. With over 15 indexed publications in high-impact journals such as Polymers, Cellulose, Macromol, and Inorganica Chimica Acta, his contributions to materials science, drug delivery, and nanotechnology have earned acclaim from the global scientific community and research peers.

Research Interests 🔬

Dr. Flores Rojas’s research centers on the synthesis and engineering of advanced materials with antimicrobial and photophysical properties. He explores gamma radiation and chemical polymerization to develop functionalized biomaterials, nanocomposites, and dendritic compounds for drug delivery, environmental cleanup, and energy transfer. His work on enzyme immobilization, organometallic catalysis, and core-shell nanoparticles integrates polymer chemistry with biomedical and environmental applications. He actively investigates biocompatibility, mechanical behavior, and surface morphology of polymers. With a multidisciplinary approach, he aims to develop smart, responsive materials for industrial, clinical, and energy-based innovations, contributing to sustainable and efficient material science solutions.

Publications

Rohit Pal | Pharmaceutical Chemistry | Young Scientist Award

Published on by Cognitive Scientist Awards

Mr. Rohit Pal | Pharmaceutical Chemistry | Young Scientist Award

PhD Scholar at Acharya and BM Reddy College of Pharmacy, Bengaluru, India

Mr. Rohit Pal is a dedicated and emerging researcher in the field of pharmaceutical sciences, particularly focusing on drug discovery and development. Currently pursuing his Ph.D. at Acharya & BM Reddy College of Pharmacy in Bengaluru, he is engaged in innovative research on Pyrimidine derivatives as fourth-generation EGFR inhibitors to combat Non-Small Cell Lung Cancer (NSCLC). With a strong academic background, including an M.Pharmacy in Pharmaceutical Chemistry, Mr. Pal combines his expertise in chemical synthesis with cutting-edge computational techniques like molecular docking and structure-activity relationship (SAR) analysis. His work spans multiple research areas, including anticonvulsant activity, anti-inflammatory research, and the pharmacognostic standardization of endangered species like Passiflora vitifolia. Throughout his career, Mr. Pal has demonstrated a capacity for both in-silico drug design and experimental testing, balancing theoretical approaches with hands-on experimentation. His impressive publication record in respected journals further showcases his capability to contribute to the scientific community. As a promising young researcher, Mr. Pal’s ongoing work not only advances pharmaceutical sciences but also holds potential for meaningful clinical applications in cancer therapy and drug design.

Profile

Orcid

 

Education 🎓

Mr. Rohit Pal’s educational background demonstrates a consistent pursuit of excellence in the field of pharmaceutical sciences. He is currently enrolled in a Ph.D. program at Acharya & BM Reddy College of Pharmacy in Bengaluru, Karnataka, where his research is focused on the development of Pyrimidine derivatives as EGFR inhibitors to target Non-Small Cell Lung Cancer (NSCLC). Prior to his doctoral studies, Mr. Pal completed his M.Pharmacy in Pharmaceutical Chemistry from ISF College of Pharmacy in Moga, Punjab, achieving a notable CGPA of 9.07. His academic journey began with a B. Pharmacy from Dev Bhoomi Institute of Pharmacy and Research, Dehradun, where he gained a robust foundation in pharmaceutical sciences. Additionally, Mr. Pal holds a D. Pharmacy from SGGS College of Pharmacy, Chandigarh, further demonstrating his dedication to the field from the onset of his academic career. His varied educational experiences have shaped his interdisciplinary approach to pharmaceutical research, combining knowledge from chemistry, biology, and computational sciences. This solid academic foundation has propelled Mr. Pal to explore complex drug development challenges, particularly in cancer therapy, with a keen interest in molecular-level drug interactions.

Work Experience 💼

Mr. Rohit Pal’s professional experience reflects a promising trajectory in pharmaceutical research and drug discovery. As a Ph.D. scholar at Acharya & BM Reddy College of Pharmacy, he is deeply involved in researching Pyrimidine derivatives for EGFR inhibition in Non-Small Cell Lung Cancer (NSCLC). His research explores the design, synthesis, and evaluation of novel drug candidates, combining in-vitro testing with computational drug design. Through the use of molecular docking and structure-activity relationship (SAR) analysis, Mr. Pal aims to identify compounds with high therapeutic potential. Beyond his Ph.D. work, Mr. Pal has worked on various other research projects, including 1,2,4-triazine derivatives for anticonvulsant activity and the anti-inflammatory properties of Passiflora vitifolia, an endangered plant species. His work spans both synthetic chemistry and biological testing, allowing him to gain expertise in pharmacological assays and computational modeling. Mr. Pal’s professional experience also includes using sophisticated instruments such as HPLC, UV spectrophotometers, and Microwave Synthesizers, which complement his experimental work and ensure the reliability of his results. These experiences have positioned him well for future leadership roles in pharmaceutical research and drug developmen

Awards and Honors

Although still in the early stages of his academic career, Mr. Rohit Pal has already garnered significant recognition for his research efforts. His academic excellence is reflected in his M.Pharmacy CGPA of 9.07, placing him among the top students in his cohort. Mr. Pal’s research has been published in reputable journals such as the Journal of Biomolecular Structure and Dynamics and Chemical Physics Impact, demonstrating the impact and quality of his work. These publications are indicative of his ability to produce research that contributes to the scientific community. Despite being early in his career, his involvement in cutting-edge research on Pyrimidine derivatives and EGFR inhibitors has already gained attention within the academic and pharmaceutical fields. His dedication to molecular docking, drug design, and pharmacognostic studies positions him for further recognition. As Mr. Pal continues to contribute to innovative drug development solutions, he is likely to receive more prestigious awards and honors, reflecting the growing importance of his work in cancer research and pharmaceutical chemistry.

Research Interests

Mr. Rohit Pal’s research interests are centered around the intersection of pharmaceutical chemistry and drug discovery. His primary focus is on developing Pyrimidine derivatives as fourth-generation EGFR inhibitors aimed at Non-Small Cell Lung Cancer (NSCLC), a serious health concern with limited therapeutic options. By targeting the epidermal growth factor receptor (EGFR), his work could offer more effective treatment alternatives for cancer patients. In addition to cancer research, Mr. Pal has explored 1,2,4-triazine derivatives for evaluating anticonvulsant activity, contributing to neurological disorder treatments. He is also interested in anti-inflammatory research, with a particular focus on Passiflora vitifolia, an endangered plant species, aiming to standardize its pharmacognostic properties. His multidisciplinary approach extends to the application of computational drug design, where he utilizes molecular docking and molecular dynamics simulations to predict drug-receptor interactions. Mr. Pal is committed to advancing drug development by combining experimental chemistry with in-silico methodologies, offering innovative solutions for complex healthcare challenges. His work on drug repurposing, targeted therapies, and sustainable drug sourcing reflects his holistic approach to addressing both scientific and global health concerns.

Research Skills

Mr. Rohit Pal possesses a wide range of research skills essential for successful pharmaceutical research. His proficiency in chemical synthesis includes techniques such as recrystallization, sublimation, and flash chromatography, which he applies to purify and isolate new compounds for testing. In addition to these laboratory techniques, Mr. Pal is highly skilled in analytical methods, including HPLC and UV spectrophotometry, to assess the purity and chemical composition of compounds. He is also adept at utilizing computational tools for drug design, particularly AutoDock, Biovia Drug Discovery Studio, and Pymol, to perform molecular docking and molecular dynamics simulations. These tools allow him to predict the interactions between drug candidates and their targets, enhancing the efficiency of drug development. Furthermore, Mr. Pal has experience in in-vitro biological testing, including assays for anticonvulsant, anti-inflammatory, and antioxidant activities, ensuring the biological relevance of his synthesized compounds. His ability to combine experimental techniques with computational modeling equips him to approach drug discovery from both theoretical and practical angles, ensuring well-rounded and impactful research outcomes.

📚 Publications

  • Design, synthesis, and biological evaluation of novel 4-(4-ethoxyphenyl)-6-(substituted-phenyl)pyrimidin-2-amine/thiol/hydroxy derivatives as EGFRWT and EGFRT790M inhibitors targeting NSCLC: In-vitro and in-silico exploration
    • Journal: Journal of Molecular Structure
    • DOI: 10.1016/j.molstruc.2024.141227
    • Date: April 2025
    • Contributors: Rohit Pal; Gurubasavaraja Swamy Purawarga Matada; Ghanshyam Teli; Viney Chawla; Pooja A. Chawla
  • Next-generation cancer therapeutics: PROTACs and the role of heterocyclic warheads in targeting resistance
    • Journal: European Journal of Medicinal Chemistry
    • DOI: 10.1016/j.ejmech.2024.117034
    • Date: January 2025
    • Contributors: Ebna Azizal Omar; Rajesh R.; Pronoy Kanti Das; Rohit Pal; Gurubasavaraja Swamy Purawarga Matada; Lalmohan Maji
  • Benzothiazole a privileged scaffold for cutting-edge anticancer agents: Exploring drug design, structure-activity relationship, and docking studies
    • Journal: European Journal of Medicinal Chemistry
    • DOI: 10.1016/j.ejmech.2024.116831
    • Date: December 2024
    • Contributors: Aayishamma I; Gurubasavaraja Swamy Purawarga Matada; Rohit Pal; Abhishek Ghara; Nimmagadda Venkata Satya Sai Aishwarya; Kumaraswamy B; Ketan R. Hosamani; Manjushree B V; Haripriya E
  • An outlook of docking analysis and structure-activity relationship of pyrimidine-based analogues as EGFR inhibitors against non-small cell lung cancer (NSCLC)
    • Journal: Journal of Biomolecular Structure and Dynamics
    • DOI: 10.1080/07391102.2023.2252082
    • Date: December 11, 2024
    • Contributors: Rohit Pal; Ghanshyam Teli; Sindhuja Sengupta; Lalmohan Maji; Gurubasavaraja Swamy Purawarga Matada
  • Exploring the anticancer potential of triazine derivatives: An outlook of designing strategies, docking studies, and structure-activity relationships (SAR)
    • Journal: ChemistrySelect
    • DOI: 10.1002/slct.202402766
    • Date: November 2024
    • Contributors: B. V. Manjushree; Gurubasavaraja Swamy Purawarga Matada; Rohit Pal; Md. Ashadul Sk; M. P. Viji; Nimmagadda Venkata Satya Sai Aishwarya; Pronoy Kanti Das; I. Aayishamma; S. Mounika
  • Pyrazole, pyrazoline, and fused pyrazole derivatives: New horizons in EGFR-targeted anticancer agents
    • Journal: Chemistry & Biodiversity
    • DOI: 10.1002/cbdv.202400880
    • Date: November 2024
    • Contributors: Ketan R Hosamani; Hemalatha K; Rohit Pal; Gurubasavaraja Swamy Purawarga Matada; Kumaraswamy B; Aayishamma I; Nimmagadda Venkata Satya Sai Aishwarya

Conclusion 

Mr. Rohit Pal is an exceptionally talented and promising researcher in the field of pharmaceutical sciences. His research, focused on Pyrimidine derivatives as EGFR inhibitors for Non-Small Cell Lung Cancer (NSCLC), is not only innovative but holds significant promise for advancing cancer treatment. His combination of chemical synthesis, computational drug design, and biological testing reflects his multidisciplinary approach to pharmaceutical research. Mr. Pal’s commitment to anti-inflammatory, anticonvulsant, and pharmacognostic standardization further demonstrates his versatility as a researcher. While still in the early stages of his career, his publication record and expertise in molecular docking and drug design suggest that he is well on his way to becoming a leader in pharmaceutical research. His ongoing work could contribute to groundbreaking advancements in cancer therapy, neurological disorder treatments, and sustainable drug sourcing. With his strong educational background, solid professional experience, and growing body of work, Mr. Rohit Pal is undoubtedly a candidate with the potential to make meaningful contributions to drug development and global health. His future in research looks bright, and he is well-positioned for recognition in upcoming awards such as the Young Scientist Award.